miR-3622b-5p regulates cisplatin resistance of human gastric cancer cell line by targeting BIRC5

Ping Zhu\(^1\), Xia Shan\(^2,3\), Jinhui Liu\(^4,\), Xin Zhou\(^2\), Huo Zhang\(^2\), Tongshan Wang\(^2\), Jianqing Wu\(^{1,5\,*}\), Wei Zhu\(^{2,5\,*}\), Ping Liu\(^2,5\,*\)

\(^1\)Jiangsu Provincial Key Laboratory of Geriatrics, Department of Geriatrics, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;  
\(^2\)Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China;  
\(^3\)Department of Respiration, the Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;  
\(^4\)Department of Obstetrics and Gynecology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;  
\(^5\)Department of Oncology, the Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, Jiangsu 215000, China.

Dual-luciferase reporter assay

The sequence of 3'UTR of human BIRC5 cDNA containing the putative target site for the miR-3622b-5p; red stands for the putative target site for miR-3622b-5p:

AGCAGAAAATGCACCTCAGCCTCTGTA
CATCTAAGCTGTCTTTATTTTGATAT
TCAGCTGTAAATGGATACTTCACTTTAATA

Supplementary Fig. 1  Computational analysis identified that BIRC5 may be a potential target of miR-3622b-5p, and the predicted binding sequences of BIRC5-3'UTR and miR-3622b-5p were marked.
Supplementary Fig. 2  The expression of BIRC5 in tissue samples of 15 cases of gastric cancer was examined by immunohistochemistry. Immunohistochemistry staining showed that BIRC5 was significantly high expressed in 4 samples, including 2 diffuse-type gastric cancer tissues and 2 intestinal-type gastric cancer tissues, with the positive rate of 26.7% (4/15). Original magnification × 200.